SCHEMBL5117945

SCHEMBL5117945

Cc1csc2nc(-c3ccno3)nc(NCc3ccc(F)cc3)c12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 8/20 0.51
CHRM4 P08173 1/20 0.40
SLC26A6 Q9BXS9 2/20 0.39
TGFBR1 P36897 1/20 0.37
THRB P10828 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
CTNNB1 P35222 1/20 0.36
TCF7L2 Q9NQB0 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
MEN1 O00255 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5118080 0.91 ESR1 (0.48) ESR1CHRM4TGFBR1ALDH1A1CYP1A2
SCHEMBL5129214 0.87 ESR1 (0.49) ESR1TGFBR1KDM4EALDH1A1SMN1; SMN2
SCHEMBL5122162 0.85 ESR1 (0.43) ESR1MEN1KMT2A
SCHEMBL5116156 0.84 ALDH1A1 (0.43) ESR1KDM4EALDH1A1CYP1A2CYP3A4
SCHEMBL5125583 0.84 ESR1 (0.42) ESR1CHRM4TGFBR1ALDH1A1CYP1A2
SCHEMBL5129882 0.83 ESR1 (0.54) ESR1TGFBR1MEN1LMNAMAPT
SCHEMBL5128647 0.83 ESR1 (0.46) ESR1CHRM4
SCHEMBL5127893 0.83 GAA (0.48) ESR1CHRM4SLC26A6RXFP1KDM4E
SCHEMBL5126310 0.81 CHRM4 (0.41) ESR1CHRM4SLC26A6THRBRXFP1
SCHEMBL5129364 0.81 HTT (0.43) ESR1SLC26A6TGFBR1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 ESR1 2256/4885CHRM4 4573/4885SLC26A6 4462/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.